Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Authors
Keywords
Medulloblastoma, HDAC, HDAC inhibitor, HDAC2, MYC
Journal
Acta Neuropathologica Communications
Volume 3, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-04-03
DOI
10.1186/s40478-015-0201-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
- (2014) Marcel Kool et al. CANCER CELL
- GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3
- (2014) J. Fabian et al. CANCER RESEARCH
- Cytogenetic Prognostication Within Medulloblastoma Subgroups
- (2014) David J.H. Shih et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
- (2014) Paul A. Northcott et al. NATURE
- Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
- (2014) Volker Hovestadt et al. NATURE
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
- (2014) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
- (2013) Volker Hovestadt et al. ACTA NEUROPATHOLOGICA
- The Role of Chromatin Remodeling in Medulloblastoma
- (2013) David T. W. Jones et al. BRAIN PATHOLOGY
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
- (2013) Dana E. Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Proposal Regarding Reporting of In Vitro Testing Results
- (2013) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
- (2013) Benjamin E. L. Lauffer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
- (2013) Marco Lodrini et al. NUCLEIC ACIDS RESEARCH
- Sonic Hedgehog-Induced Histone Deacetylase Activation Is Required for Cerebellar Granule Precursor Hyperplasia in Medulloblastoma
- (2013) Seung Joon Lee et al. PLoS One
- Histone deacetylase 10 promotes autophagy-mediated cell survival
- (2013) I. Oehme et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma
- (2012) Adrian M. Dubuc et al. ACTA NEUROPATHOLOGICA
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
- (2012) Marcel Kool et al. ACTA NEUROPATHOLOGICA
- Nestin Expression Identifies Ependymoma Patients with Poor Outcome
- (2012) Till Milde et al. BRAIN PATHOLOGY
- Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring
- (2012) Anthony E Rizzardi et al. Diagnostic Pathology
- Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
- (2012) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
- HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment
- (2012) Till Milde et al. JOURNAL OF NEURO-ONCOLOGY
- Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations
- (2012) Trevor J. Pugh et al. NATURE
- Novel mutations target distinct subgroups of medulloblastoma
- (2012) Giles Robinson et al. NATURE
- Dissecting the genomic complexity underlying medulloblastoma
- (2012) David T. W. Jones et al. NATURE
- Raise standards for preclinical cancer research
- (2012) C. Glenn Begley et al. NATURE
- Subgroup-specific structural variation across 1,000 medulloblastoma genomes
- (2012) Paul A. Northcott et al. NATURE
- Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma
- (2012) Eric J. Sherman et al. THYROID
- MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma
- (2011) Alfa H. C. Bai et al. ACTA NEUROPATHOLOGICA
- A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
- (2011) Till Milde et al. ACTA NEUROPATHOLOGICA
- Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples
- (2011) Paul A. Northcott et al. ACTA NEUROPATHOLOGICA
- Molecular subgroups of medulloblastoma: the current consensus
- (2011) Michael D. Taylor et al. ACTA NEUROPATHOLOGICA
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
- (2011) Hendrik Witt et al. CANCER CELL
- Belinostat: clinical applications in solid tumors and lymphoma
- (2011) L Rhoda Molife et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Believe it or not: how much can we rely on published data on potential drug targets?
- (2011) Florian Prinz et al. NATURE REVIEWS DRUG DISCOVERY
- HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth
- (2010) T. Milde et al. CLINICAL CANCER RESEARCH
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
- (2010) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- Drug–target residence time: critical information for lead optimization
- (2010) Hao Lu et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells
- (2010) Dilli Ram Bhandari et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
- (2010) Yoon-Jae Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Medulloblastoma Comprises Four Distinct Molecular Variants
- (2010) Paul A. Northcott et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemical phylogenetics of histone deacetylases
- (2010) James E Bradner et al. Nature Chemical Biology
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors
- (2009) Pierre Tessier et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antitumor Effects of a Combined 5-Aza-2'Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice
- (2009) I. Ecke et al. CANCER RESEARCH
- Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and theMYCandMYCNLoci
- (2009) Stefan Pfister et al. JOURNAL OF CLINICAL ONCOLOGY
- High-throughput detection and multiplex identification of cell contaminations
- (2009) M. Schmitt et al. NUCLEIC ACIDS RESEARCH
- HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells
- (2008) Dennis Wegener et al. ANTI-CANCER DRUGS
- Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases
- (2008) Philip Jones et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
- Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
- (2008) C. James Chou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started